Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword

Prevalence of non-valvular atrial fibrillation is increasing over time. Particularly in elderly population, treatment strategies to reduce the rate of stroke are challenging and still represent an unsolved cultural question. Indeed, the risk of thromboembolism increases in the elderly in parallel wi...

Full description

Bibliographic Details
Main Authors: Francesco Vetta, Gabriella Locorotondo, Giampaolo Vetta
Format: Article
Language:English
Published: PAGEPress Publications 2017-07-01
Series:Geriatric Care
Subjects:
Online Access:http://www.pagepressjournals.org/index.php/gc/article/view/6371
id doaj-8a4e31f2f49f4cecae2d3e446d27886b
record_format Article
spelling doaj-8a4e31f2f49f4cecae2d3e446d27886b2020-11-25T03:39:10ZengPAGEPress PublicationsGeriatric Care2465-11092465-13972017-07-013210.4081/gc.2017.63715338Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged swordFrancesco Vetta0Gabriella Locorotondo1Giampaolo Vetta2Cardiology Unit, Israelite Hospital, RomeCardiology Unit, Israelite Hospital, Rome; Institute of Cardiology, Catholic University of the Sacred Heart, RomeCardiology Unit, Israelite Hospital, Rome; Institute of Cardiology, Campus Bio-Medico University, RomePrevalence of non-valvular atrial fibrillation is increasing over time. Particularly in elderly population, treatment strategies to reduce the rate of stroke are challenging and still represent an unsolved cultural question. Indeed, the risk of thromboembolism increases in the elderly in parallel with the risk of bleeding. The frequent coexistence of several morbidities, frailty syndrome, polypharmacy, chronic kidney disease and dementia strengthens the perception that risk-benefit ratio of anticoagulant therapy could be unfavorable, and explains why such treatment is underused in the elderly. Recently, the introduction of non-vitamin K oral anticoagulants (NOACs) has allowed us to overcome the large number of limitations imposed by the use of vitamin K antagonists. In this manuscript, the benefits of individual NOACs in comparison with warfarin in elderly patients are reviewed. Targeted studies on complex elderly patients are needed to test usefulness of a geriatric comprehensive assessment, besides the scores addressing risk of thromboembolic and hemorrhagic events. In the meantime, it is mandatory that use of anticoagulant therapy in most elderly people, currently excluded from randomized controlled trials, is prudent and responsible.http://www.pagepressjournals.org/index.php/gc/article/view/6371Atrial fibrillationnon-vitamin K antagonist oral anticoagulationwarfarinelderlystrokehemorrhagefrailty.
collection DOAJ
language English
format Article
sources DOAJ
author Francesco Vetta
Gabriella Locorotondo
Giampaolo Vetta
spellingShingle Francesco Vetta
Gabriella Locorotondo
Giampaolo Vetta
Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword
Geriatric Care
Atrial fibrillation
non-vitamin K antagonist oral anticoagulation
warfarin
elderly
stroke
hemorrhage
frailty.
author_facet Francesco Vetta
Gabriella Locorotondo
Giampaolo Vetta
author_sort Francesco Vetta
title Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword
title_short Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword
title_full Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword
title_fullStr Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword
title_full_unstemmed Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword
title_sort anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword
publisher PAGEPress Publications
series Geriatric Care
issn 2465-1109
2465-1397
publishDate 2017-07-01
description Prevalence of non-valvular atrial fibrillation is increasing over time. Particularly in elderly population, treatment strategies to reduce the rate of stroke are challenging and still represent an unsolved cultural question. Indeed, the risk of thromboembolism increases in the elderly in parallel with the risk of bleeding. The frequent coexistence of several morbidities, frailty syndrome, polypharmacy, chronic kidney disease and dementia strengthens the perception that risk-benefit ratio of anticoagulant therapy could be unfavorable, and explains why such treatment is underused in the elderly. Recently, the introduction of non-vitamin K oral anticoagulants (NOACs) has allowed us to overcome the large number of limitations imposed by the use of vitamin K antagonists. In this manuscript, the benefits of individual NOACs in comparison with warfarin in elderly patients are reviewed. Targeted studies on complex elderly patients are needed to test usefulness of a geriatric comprehensive assessment, besides the scores addressing risk of thromboembolic and hemorrhagic events. In the meantime, it is mandatory that use of anticoagulant therapy in most elderly people, currently excluded from randomized controlled trials, is prudent and responsible.
topic Atrial fibrillation
non-vitamin K antagonist oral anticoagulation
warfarin
elderly
stroke
hemorrhage
frailty.
url http://www.pagepressjournals.org/index.php/gc/article/view/6371
work_keys_str_mv AT francescovetta anticoagulationtherapyintheelderlywithnonvalvularatrialfibrillationadoubleedgedsword
AT gabriellalocorotondo anticoagulationtherapyintheelderlywithnonvalvularatrialfibrillationadoubleedgedsword
AT giampaolovetta anticoagulationtherapyintheelderlywithnonvalvularatrialfibrillationadoubleedgedsword
_version_ 1724540402261819392